ESE vs BMI vs ITRI vs NOVT

For growth investors, ESCO Technologies Inc.

(ESE) is the stronger pick with 19. 2% revenue growth year-over-year, versus -3. 0% for Itron, Inc. (ITRI). Itron, Inc. (ITRI) offers the better valuation at 12. 5x trailing P/E (13. 5x forward), making it the more compelling value choice. Analysts rate ESCO Technologies Inc. (ESE) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Itron, Inc.

(ITRI) is the cheapest at 12. 5x versus Novanta Inc. at 92. 7x. On forward P/E, Itron, Inc. is actually cheaper at 13. 5x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: ESCO Technologies Inc. wins at 0. 61x versus Novanta Inc. 's 11. 61x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, ESCO Technologies Inc.

(ESE) delivered a total return of +205. 5%, compared to -7. 2% for Itron, Inc. (ITRI). Over 10 years, the gap is even starker: NOVT returned +853. 7% versus ITRI's +94. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Badger Meter, Inc.

(BMI) is the lower-risk stock at 0. 87β versus Novanta Inc. 's 2. 02β — meaning NOVT is approximately 133% more volatile than BMI relative to the S&P 500. On balance sheet safety, ESCO Technologies Inc. (ESE) carries a lower debt/equity ratio of 15% versus 74% for Itron, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ESCO Technologies Inc.

(ESE) is pulling ahead at 19. 2% versus -3. 0% for Itron, Inc. (ITRI). On earnings-per-share growth, the picture is similar: ESCO Technologies Inc. grew EPS 193. 1% year-over-year, compared to -16. 9% for Novanta Inc.. Over a 3-year CAGR, BMI leads at 17. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ESCO Technologies Inc.

(ESE) is the more profitable company, earning 27. 3% net margin versus 5. 5% for Novanta Inc. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BMI leads at 20. 0% versus 11. 9% for NOVT. At the gross margin level — before operating expenses — NOVT leads at 44. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, ESCO Technologies Inc. (ESE) is the more undervalued stock at a PEG of 0. 61x versus Novanta Inc. 's 11. 61x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Itron, Inc. (ITRI) trades at 13. 5x forward P/E versus 40. 9x for ESCO Technologies Inc. — 27. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ITRI: 68. 8% to $137. 00.

In this comparison, BMI (1.

2% yield) pays a dividend. ESE, ITRI, NOVT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Badger Meter, Inc.

(BMI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 87), 1. 2% yield, +253. 6% 10Y return). Itron, Inc. (ITRI) carries a higher beta of 1. 53 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BMI: +253. 6%, ITRI: +94. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Technology sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ESE is a small-cap high-growth stock; BMI is a small-cap quality compounder stock; ITRI is a small-cap deep-value stock; NOVT is a small-cap quality compounder stock. BMI pays a dividend while ESE, ITRI, NOVT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.